Background: 5-Fluorouracil (5-FU)-based regimens have not been shown to prolong survival or provide clinical benefit in patients with advanced pancreatic cancer. The purpose of this study was to determine the tolerability of protracted venous infusion (PVI) of 5-FU, modulated by a low dose of the synthetic antifolate trimetrexate, in patients with advanced pancreatic cancer. Results: Twenty-two patients were assessable. The maximum tolerated dose of trimetrexate was 40 mg/m 2 . The most common grade 3 and 4 toxicity was diarrhea. There were no treatment-related deaths. Preliminary analysis of activity revealed a response rate of 9%, with 41% of the patients having stable disease for a median duration of 3.8 months. The median survival for the entire group was 6.9 months (range 1-29 months). A clinical benefit response was experienced by 27.2% of patients.
Introduction
Pancreatic cancer is a lethal disease, for which the current treatment is of limited value. Over 80% of patients present with locally advanced or metastatic disease, a situation where current therapy results in only modest clinical benefit, without a major impact on survival [1, 2] . 5-Fluorouracil (5-FU) administered in bolus form is the most extensively studied drug. Objective responses to bolus 5-FU occur in <10% of patients, without an impact on overall survival or quality of life [3] [4] [5] [6] [7] [8] [9] . Protracted venous infusion (PVI) of 5-FU allows for higher dose intensity than bolus administration, is associated with a different toxicity profile and seems to have a higher response rate and a marginal survival benefit in colorectal cancer patients [10] . Doses of 200-300 mg/m 2 /day of 5-FU have been employed in advanced pancreatic cancer as a single agent or in combinations [11] [12] [13] [14] [15] [16] . Response rates to PVI 5-FU have ranged from 8 to 19%.
Trimetrexate is a synthetic folate analog, which potently inhibits dihydrofolate reductase (DHFR) [17] [18] [19] . As a result of inhibition of purine synthesis, trimetrexate increases intracellular levels of phosphoribosyl pyrophosphate (PRPP), a cofactor for the enzyme orotate phosphoribosyltransferase, which is required for the intracellular conversion of 5-FU to active fluorinated nucleotides. These fluoronucleotides are incorporated into RNA, thus potentiating 5-FU cytotoxicity [20, 21] . Trimetrexate has been reported to enhance the cytotoxicity of 5-FU and folinic acid in vitro [22] in a scheduledependent manner [20, 23, 24] . Based on these preclinical results, sequential administration of trimetrexate has been studied in patients with colorectal cancer using schedules that employ bolus 5-FU [21, 25] .
It is unknown whether trimetrexate-mediated 5-FU modulation occurs using PVI 5-FU. As indicated, increased levels of PRPP mediate RNA and protein synthesis inhibition. However, the putative primary mechanism of action of PVI 5-FU is inhibition of thymidylate synthase (TS), rather than RNA synthesis [26] [27] [28] . Several lines of evidence lend support to the possibility of synergy between trimetrexate and PVI 5-FU, based on potentiation of TS inhibition in the absence of folinic acid. First, elevation of intracellular PRPP results in increased levels of 5-fluorodeoxyuridine monophosphate (FdUMP), the 5-FU nucleotide involved in TS inhibition. Secondly, inhibition of DHFR by methotrexate is associated with an increase in intracellular levels of dihydrofolate polyglutamates [29] . These metabolites, like folinic acid [30] , can complex with TS and FdUMP to enhance TS inhibition [31] .
Based on the activity and favorable toxicity profile of PVI 5-FU in phase II studies, which suggests synergy between trimetrexate and 5-FU, and on the above rationale for a potential modulatory effect on PVI 5-FU by trimetrexate, we conducted this dose escalation trial in previously untreated patients with advanced pancreatic cancer. The main objectives of this study were to assess toxicity and to determine maximum tolerated dose. Secondary objectives were response rate, time to treatment failure, survival and clinical benefit.
Patients and methods

Patients
Patients ≥18 years of age, with histologically confirmed adenocarcinoma of the pancreas, either locally advanced (unresectable stages II and III) or metastatic (stage IV) were eligible. A Karnofsky performance status (KPS) of ≥60% was required. Patients who had lost >10% of their weight within the previous 2 months were ineligible. Patients who had received previous chemotherapy for advanced metastatic pancreatic cancer were also excluded, but adjuvant chemoradiotherapy was allowed. All patients had bi-dimensionally measurable disease. Patients who had received previous radiotherapy were required to have measurable disease outside the radiation port, or measurable progressive disease in the radiation port. An adequate baseline bone marrow function was necessary, defined as an absolute neutrophil count (ANC) ≥1500/mm 3 and a platelet count ≥100 000/mm 3 . Adequate renal function (defined as serum creatinine ≤2.0 mg/dl) and hepatic function (defined as serum bilirubin ≤2.0 mg/dl, serum albumin ≥2.5 mg/dl and AST ≤3 × the upper limit of normal in the absence of liver metastasis, or ≤5 × the upper limit of normal in the presence of liver metastasis) were also required. Informed consent was obtained before study entry. This study was performed with the approval of the local human subject protection committee.
Treatment
All patients were treated on an outpatient basis. Patients underwent placement of a central venous catheter for PVI 5-FU infusion. Patients were entered into one of four cohorts to receive trimetrexate glucuronate at 20, 30, 40 or 50 mg/m 2 weekly. As folinic acid can exacerbate the toxicity associated with PVI 5-FU, we used lower doses of trimetrexate than those previously employed [21, 25] to avoid the need for folinic acid rescue. We performed dose escalation after treatment of five patients in a prior cohort had been completed without excessive toxicity. In the event that three patients in any given cohort experienced grade 3 or 4 toxicity, dose escalation was terminated and all remaining patients were to be enrolled at the preceding dose level. All patients remained in their cohort of entry until discontinuation from the study. A treatment cycle was defined as 8 weeks and included 6 weeks of chemotherapy followed by a 2-week rest period. Treatment cycles were repeated until either disease progression or unacceptable toxicity supervened. 
Dose modifications
All toxicities were graded using the NCI Common Toxicity Criteria version 1. Patients were evaluated weekly for toxicity. In the event of a grade 2 hematological toxicity, the dose of trimetrexate was reduced by 25%. For grade 3 or 4 hematological toxicity, both trimetrexate and 5-FU were withheld until blood counts returned to ANC >2000/mm 3 and platelets >100 000/mm 3 , then the dose of trimetrexate was reduced by 25% for grade 3 and 50% for grade 4, and 5-FU was resumed at a dose of 225 mg/m 2 . For grade 2, or greater, mucosal ulceration or diarrhea, 5-FU and trimetrexate were discontinued until symptom resolution, and then the doses were resumed as follows: unmodified for grade 2; reduced by 10% for 5-FU and 25% for trimetrexate in the event of grade 3; and by 20 and 50%, respectively, in the event of grade 4. For hand-foot syndrome (including pain, erythema, swelling and tenderness in hands and/or feet), both agents were discontinued and treatment was resumed after resolution of symptoms with full dose trimetrexate, 90% dose-reduced 5-FU for grade 3 and 80% for grade 4. The duration of the cycles was not prolonged to compensate for toxicity-related treatment interruptions. Patients whose doses were withheld for 3 consecutive weeks because of any toxicity were terminated from the study.
Assessment of efficacy
Standard radiographic criteria for response were used. Survival and time to treatment failure were assessed prospectively. Clinical benefit analysis was performed using a modified version of methods previously described [4] , in which weight was considered a primary measure along with pain and functional status, measured using the KPS scale. Data on these parameters were collected weekly. The pain parameter was a composite of information obtained on pain score and analgesic consumption. Information on pain score was obtained weekly from a brief pain inventory. Records of analgesic consumption were normalized to milligrams of oral morphine sulfate over a 1-week period. KPS was assessed by two observers. Patients were classified as positive, stable or negative for each of the three parameters. To be considered as positive or negative in any parameter, improvements or deteriorations had to be sustained for at least 28 days. Pain was scored as positive if it improved ≥50% from baseline (assuming an initial minimum pain score of ≥2 on a 0-10 scale), as negative if it worsened over baseline and as stable for all other results. Analgesic consumption was scored as positive if it decreased ≥50% from baseline (assuming an initial minimum of ≥5 mg of morphine), as negative if it increased from baseline and as stable if any other result. If both pain score and analgesic consumption were positive, or if one was positive and the other remained stable, the patient was classified as positive for clinical pain score. If either or both were negative, the patient was classified as a non-responder and if both remained unchanged the patient was classified as stable. Weight parameter was scored as positive if dry weight increased by ≥7% from baseline, as negative if it decreased by ≥4% and stable for all other results. KPS score was considered as positive if it increased by ≥20%, as negative if it decreased by ≥20% and as stable for all other results. Patients were classified as positive for overall clinical benefit if at least one of the parameters improved without deterioration of the others and as non-responder if all three parameters remained stable or if any deteriorated.
Statistical methods
Patient survival and time to disease progression were measured in days from study entry and data were summarized by Kaplan-Meier survivor function estimates and associated confidence intervals. Cox proportional hazards regression was used to assess the effects of trimetrexate dose, treatment time and baseline patient characteristics, on survival and time to progressive disease. Differential incidence of toxicity events across dose levels was analyzed by the χ 2 test of equivalent incidence, and associations between trimetrexate dose and toxicity grade were analyzed by the χ 2 test of association.
Results
Patient demographics
From February 1998 to August 1999, 23 patients were enrolled in this university-based multicenter study in which nine community oncology sites participated. One patient enrolled in the 50 mg/m 2 trimetrexate dose cohort withdrew before receiving treatment and is not included in the analysis. All other patients were included in an intention-to-treat analysis, including one patient, enrolled in the 40 mg/m 2 cohort, who voluntarily discontinued therapy after 1 week on the study. The total number of cycles administered was 45 (median 1, range 1-8) over four dose levels of trimetrexate. Patient characteristics and treatment groups are shown in Table 1 .
Toxicity
Seven patients required dose modifications because of toxicity; in four of them toxicity was grade 3 or 4. One patient (a radiographic and clinical benefit responder) had to be withdrawn from the study because of repeated dose reductions and treatment discontinuations for grade 2 mucositis and handfoot syndrome. This patient was enrolled on the trimetrexate cohort receiving 20 mg/m 2 . No other toxicity-related study discontinuations occurred. Out of 230 administered doses of trimetrexate and 5-FU in this study, 6% of the doses were withheld because of toxicity, and dose modifications were implemented in 7.3% of the trimetrexate doses and 3.5% of the 5-FU doses. Dose reductions or discontinuations occurred in 21% of patients in cohorts receiving 20-40 mg/m 2 trimetrexate, and 50% of patients in the 50 mg/m 2 cohort.
There were no treatment-related deaths. Grade 3 and 4 toxicity is shown in Table 2 . The most common toxicity event leading to drug modification or discontinuation was diarrhea. Diarrhea was also the most common grade 3 and 4 toxicity overall (23% of all patients). Three patients, or 50% of the cohort treated at the 50 mg/m 2 dose, experienced grade 4 diarrhea. Therefore, diarrhea was considered the dose-limiting toxicity. One patient in the 50 mg/m 2 group experienced a non-neutropenic septic episode that resolved with antibiotic treatment. There were no catheter-related thrombotic epi- sodes, grades 3 or 4, stomatitis, hand-foot syndrome or hypersensitivity reactions. The most common grade 1 and 2 nonhematological toxicities were nausea and vomiting (55%), cutaneous (50%), stomatitis (45%), diarrhea (32%) and handfoot syndrome (27%). With regard to hematological toxicity, grades 1 and 2 neutropenia, anemia and thrombocytopenia occurred in 9, 27 and 27% of patients, respectively, across all four cohorts. There were no grade 4 hematological toxicity events. One patient in the 40 mg/m 2 cohort experienced grade 3 anemia and neutropenia.
When all toxicity categories were analyzed together their grade was found to increase significantly with the dose of trimetrexate (P = 0.008). In addition, the total number of toxic events, irrespective of their grade, tended to increase with the dose of trimetrexate (P = 0.062). The maximum tolerated and recommended dose of trimetrexate for future investigation using this combination schema dose was determined to be 40 mg/m 2 .
Activity
Twenty-two patients were assessable for radiographic response. Two patients experienced a partial response (response rate 9%) and nine patients (41%) had stable disease for at least 8 weeks. The two responses lasted 3 and 3.9 (Figure 1 ). The median survival for the entire group was 6.9 months (range 1-29 months) and the 1-year survival was 27% (Figure 2 ). For patients with stage IV disease, median and 1-year survivals were 6.7 months and 26%, respectively. No correlation was observed between baseline patient characteristics or trimetrexate dose, and time to treatment failure or survival. At the time of this analysis, the two responders remain alive at 32 and 25 months from initiation of therapy.
Six patients fulfilled the criteria for clinical benefit response, for a total response rate of 27.2%. Three patients fulfilled these criteria on the basis of improvements in pain scores with stable weight and KPS scores, one had an improvement in pain with the other two parameters remaining stable during one cycle, followed on the subsequent cycle by an improvement in weight with stable pain and KPS scores, and two patients qualified for a response on the basis of an improvement in weight with stable pain and KPS scores. Of the six patients, one was classified as a partial radiographic responder and the remaining five patients had stable disease. The second radiographic responder did not qualify for a clinical benefit response as all three parameters remained stable throughout the duration of therapy.
Discussion
We undertook this study to determine the maximum tolerated dose and the toxicity of the combination of low-dose trimetrexate and PVI 5-FU without folinic acid in patients with advanced pancreatic cancer. To our knowledge, this study represents the first report of PVI 5-FU modulation using an antifolate. Doses of 40 and 225 mg/m 2 of trimetrexate and 5-FU, respectively, were well tolerated, without incidence of grade 4 toxicity. Diarrhea was the most common severe toxicity, with grades 3 and 4 occurring in 23% of all patients, 60% of these in the cohort receiving trimetrexate at a dose of 50 mg/m 2 . Given that the toxicity of this regimen correlates with trimetrexate dose and biochemical evidence of modulation exists for relatively low doses of this drug [21] , we have chosen 40 mg/m 2 as the dose of trimetrexate for future investigations. The relative paucity of severe toxicity using doses of trimetrexate below 50 mg/m 2 contrasts with that of previously reported results from phase I and II studies using higher doses of trimetrexate as a single agent. In those studies, the major toxicity of trimetrexate was myelosuppression [17, 32, 33] . The toxicity profile of the current study also compares favorably with that of previously reported double modulation 5-FU schedules with folinic acid rescue [21, 25] . The current treatment schema is simpler to administer, as treatments are scheduled only once weekly and do not require oral folinic acid to rescue trimetrexate toxicity.
In the present study, response seemed to correlate with survival; the two patients that experienced a radiographic response (one with metastatic and one with locally advanced disease) remain alive at 32 and 25 months from initiation of therapy. As a secondary objective of this study, we sought to obtain preliminary evidence of clinical improvement, because symptom control is an important endpoint in the treatment of advanced pancreatic cancer. Our analysis showed a clinical benefit response rate of 27%. However, because the main endpoint of this study was dose finding, with patients treated across a range of trimetrexate doses, these efficacy results should be considered preliminary. It should also be noted that, although the study was opened to community oncologists, reducing the possibility of selection bias, extrapolating these toxicity and activity results to routine clinical practice should take into account that most patients had well-preserved performance status, a relatively uncommon situation in patients presenting with advanced pancreatic cancer.
It is not known whether trimetrexate-mediated 5-FU modulation resulted in enhanced activity over that obtained with unmodulated PVI 5-FU. A randomized study would be required to establish the role of trimetrexate in this treatment schedule. Any benefit of the combination of trimetrexate and 5-FU is unlikely to be derived from a direct cytotoxic action of trimetrexate, as previous studies indicate that trimetrexate, as a single agent, is inactive against pancreatic cancer [34, 35] . Given that 5-FU and gemcitabine do not exhibit cross- resistance in this disease [36] , it is conceivable that the regimen described here combined with gemcitabine may result in additive or synergistic activity. The reproducible activity of regimens containing un-modulated PVI 5-FU [12] [13] [14] [15] 37] and the results reported herein, support further exploration of PVI 5-FU combinations in pancreatic cancer.
